Lela M. Lucy

1.6k total citations
8 papers, 308 citations indexed

About

Lela M. Lucy is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Lela M. Lucy has authored 8 papers receiving a total of 308 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Hematology, 4 papers in Genetics and 3 papers in Molecular Biology. Recurrent topics in Lela M. Lucy's work include Acute Myeloid Leukemia Research (4 papers), Multiple Myeloma Research and Treatments (3 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (3 papers). Lela M. Lucy is often cited by papers focused on Acute Myeloid Leukemia Research (4 papers), Multiple Myeloma Research and Treatments (3 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (3 papers). Lela M. Lucy collaborates with scholars based in Italy, Germany and France. Lela M. Lucy's co-authors include S. Vincent Rajkumar, W Wiktor-Jędrzejczak, Laura Rosiñol, Marta Olesnyckyj, Zhinuan Yu, John Catalano, Robert Knight, Jerome B. Zeldis, Joan Bladé and Mohamad A. Hussein and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Haematologica.

In The Last Decade

Lela M. Lucy

8 papers receiving 302 citations

Peers

Countries citing papers authored by Lela M. Lucy

Since Specialization

Citations

This map shows the geographic impact of Lela M. Lucy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lela M. Lucy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lela M. Lucy more than expected).

Fields of papers citing papers by Lela M. Lucy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lela M. Lucy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lela M. Lucy. The network helps show where Lela M. Lucy may publish in the future.

Co-authorship network of co-authors of Lela M. Lucy

This figure shows the co-authorship network connecting the top 25 collaborators of Lela M. Lucy. A scholar is included among the top collaborators of Lela M. Lucy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lela M. Lucy. Lela M. Lucy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

#	Work	Indexed citations
1	The Safety and Tolerability of Azacitidine (AZA) Are Comparable in Patients with Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndromes (MDS) 2015 ·Blood ·John F. Seymour, Lewis R. Silverman, Hartmut Döhner, Pierre Fenaux, Ghulam J. Mufti, Valeria Santini, Mark D. Minden, Richard M. Stone, Lela M. Lucy, (unknown), (unknown), (unknown), (unknown), C.L. Beach, Hervé Dombret	2
2	Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial 2011 ·Haematologica ·Martin Kropff, (unknown), Jens Hillengaß, Tadeusz Robak, Roman Hájek, Peter Liebisch, Vesselina Goranova‐Marinova, C. Hulin, J Bladé, Tommaso Caravita, Hervé Avet‐Loiseau, Thomas Moehler, (unknown), Lela M. Lucy, (unknown), Axel Glasmacher, Robert Zerbib, (unknown)	43
3	Re-Evaluation of the Efficacy of Azacitidine (AZA) In Patients From the AZA-001 Study with Higher-Risk Myelodysplastic Syndromes (MDS) Classified by WHO Criteria and WPSS Risk 2010 ·Blood ·Norbert Gattermann, Guillermo Sanz, Aristoteles Giagounidis, John F. Seymour, Pierre Fenaux, Valeria Santini, Ghulam J. Mufti, Petra Muus, Fernando Ramos, Lela M. Lucy, C.L. Beach, Lewis R. Silverman	1
4	Achievement of Red Blood Cell (RBC) Transfusion Independence with Azacitidine (AZA) Leads to Improved Survival In Patients with Higher-Risk Myelodysplasias Regardless of Baseline Transfusion Needs 2010 ·Blood ·John F. Seymour, Valeria Santini, Pierre Fenaux, Aristoteles Giagounidis, Guillermo Sanz, Carlo Finelli, Lela M. Lucy, Jay T. Backstrom, C.L. Beach	2
5	AN EVALUATION OF THE ASSOCIATION OF CDKN2B (P15) DNA METHYLATION WITH RESPONSE AND SURVIVAL IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS) TREATED IN THE AZA-001 TRIAL 2010 ·Research Portal (King's College London) ·(unknown), Ghulam Mufti, Kyle J. MacBeth, J.F. Seymour, Pierre Fenaux, Steven D. Gore, Valeria Santini, Lela M. Lucy, C. L. Beach	2
6	OPTIMUM Dose of Thalidomide for Relapsed Multiple Myeloma. 2009 ·Blood ·Martin Kropff, (unknown), Jens Hillengaß, Tadeusz Robak, Roman Hájek, Peter Liebisch, Vesselina Goranova‐Marinova, Cyrille Hulin, Joan Bladé, (unknown), Hervé Avet‐Loiseau, Thomas Moehler, (unknown), Lela M. Lucy, (unknown), Axel Glasmacher, Robert Zerbib, Thierry Façon	1
7	Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Thalidomide Plus Dexamethasone Compared With Dexamethasone As Initial Therapy for Newly Diagnosed Multiple Myeloma 2008 ·Journal of Clinical Oncology ·S. Vincent Rajkumar, Laura Rosiñol, Mohamad A. Hussein, John Catalano, W Wiktor-Jędrzejczak, Lela M. Lucy, Marta Olesnyckyj, Zhinuan Yu, Robert Knight, Jerome B. Zeldis, Joan Bladé	256
8	Differential costs and outcomes among pediatric oral antibiotic formulations identified from a large prescription database. 2000 ·PubMed ·Lee Bowman, Dorothea Faulkner, Lela M. Lucy	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact